Authors: CREAVEN PJ PENDYALA L MEROPOL NJ CLENDENINN NJ WU EY LOEWEN GM PROEFROCK A JOHNSTON A DIXON M

Citation: Pj. Creaven et al., INITIAL CLINICAL-TRIAL AND PHARMACOKINETICS OF THYMITAQ(TM) (AG337) BY 10-DAY CONTINUOUS-INFUSION IN PATIENTS WITH ADVANCED SOLID TUMORS, Cancer chemotherapy and pharmacology, 41(2), 1998, pp. 167-170

Authors: KHORSAND M LANGE J FEUN L CLENDENINN NJ COLLIER M WILDING G

Citation: M. Khorsand et al., PHASE-II TRIAL OF ORAL PIRITREXIM IN ADVANCED, PREVIOUSLY TREATED TRANSITIONAL-CELL CANCER OF BLADDER, Investigational new drugs, 15(2), 1997, pp. 157-163

Authors: ODWYER PJ LAUB PB DEMARIA D QIAN MX REILLY D GIANTONIO B JOHNSTON AL WU EY BAUMAN L CLENDENINN NJ GALLO JM

Citation: Pj. Odwyer et al., PHASE-I TRIAL OF THE THYMIDYLATE SYNTHASE INHIBITOR AG331 AS A 5-DAY CONTINUOUS-INFUSION, Clinical cancer research, 2(10), 1996, pp. 1685-1692

Authors: FEUN LG ROBINSON WA SAVARAJ N GONZALEZ R LIEBMANN A OFFENHAUSER K CLENDENINN NJ

Citation: Lg. Feun et al., PHASE-II TRIAL OF PIRITREXIM AND DTIC USING AN ALTERNATING DOSE SCHEDULE IN METASTATIC MELANOMA, American journal of clinical oncology, 18(6), 1995, pp. 488-490

Authors: BERLIN J KING AC TUTSCH K FINDLAY JW KOHLER P COLLIER M CLENDENINN NJ WILDING G

Citation: J. Berlin et al., A PHASE-II STUDY OF VINBLASTINE IN COMBINATION WITH ACRIVASTINE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Investigational new drugs, 12(2), 1994, pp. 137-141